Effect of infliximab on quality of life in patients with ankylosing spondylitis according to sf-36 questionnaire data
Objective: to evaluate the effect of infliximab (INF) on quality of life (QL) in patients with ankylosing spondylitis (AS), by analyzing the results of a SF-36 questionnaire survey. Subjects and methods. Sixty-six male patients, diagnosed with AS (according to the 1984 modified New-York criteria) in...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2013-10-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/495 |
| _version_ | 1797876829794598912 |
|---|---|
| author | Tatyana Alekseevna Raskina O A Pirogova Zh A Pivovarova |
| author_facet | Tatyana Alekseevna Raskina O A Pirogova Zh A Pivovarova |
| author_sort | Tatyana Alekseevna Raskina |
| collection | DOAJ |
| description | Objective: to evaluate the effect of infliximab (INF) on quality of life (QL) in patients with ankylosing spondylitis (AS), by analyzing the results of a SF-36 questionnaire survey. Subjects and methods. Sixty-six male patients, diagnosed with AS (according to the 1984 modified New-York criteria) in its extensive or end stage with a high activity (BASDAI ≥4.0), were followed up. All the patients were divided into 2 groups according to the option of disease-modifying antirheumatic drug therapy: 1) 16 patients who received combination therapy with INF given as a standard regimen at 0, 2, and 6 weeks followed by a regimen of 5 mg/kg body weight and nonsteroidal anti-inflammatory drugs (NSAIDs) in standard doses every 8 weeks; 2) 50 patients who had monotherapy with NSAIDs in the same doses. QL was assessed using the Short-Form 36 (SF-36) questionnaire in patients with AS. Results. The scales evaluating physical health showed the greatest group differences in pain intensity (38.42%; p<0.0001) and the least in the general health status (24.48%; p<0.001). Those assessing mental health displayed statistically significant group differences in vital activity (24.78%; p<0.01).Conclusion. The patients receiving monotherapy with NSAIDs were found to have lower scores in all SF-36 scales than those on combination therapy with INF and NSAIDs. |
| first_indexed | 2024-04-10T02:07:27Z |
| format | Article |
| id | doaj.art-5d719a0e6fd14101abab4d585c6cdac3 |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:07:27Z |
| publishDate | 2013-10-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-5d719a0e6fd14101abab4d585c6cdac32023-03-13T08:39:23ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2013-10-0173475010.14412/1996-7012-2013-131800Effect of infliximab on quality of life in patients with ankylosing spondylitis according to sf-36 questionnaire dataTatyana Alekseevna Raskina0O A Pirogova1Zh A Pivovarova2ГБОУ ВПО «Кемеровская государственная медицинская академия» Минздрава РоссииГБОУ ВПО «Кемеровская государственная медицинская академия» Минздрава РоссииГБОУ ВПО «Кемеровская государственная медицинская академия» Минздрава РоссииObjective: to evaluate the effect of infliximab (INF) on quality of life (QL) in patients with ankylosing spondylitis (AS), by analyzing the results of a SF-36 questionnaire survey. Subjects and methods. Sixty-six male patients, diagnosed with AS (according to the 1984 modified New-York criteria) in its extensive or end stage with a high activity (BASDAI ≥4.0), were followed up. All the patients were divided into 2 groups according to the option of disease-modifying antirheumatic drug therapy: 1) 16 patients who received combination therapy with INF given as a standard regimen at 0, 2, and 6 weeks followed by a regimen of 5 mg/kg body weight and nonsteroidal anti-inflammatory drugs (NSAIDs) in standard doses every 8 weeks; 2) 50 patients who had monotherapy with NSAIDs in the same doses. QL was assessed using the Short-Form 36 (SF-36) questionnaire in patients with AS. Results. The scales evaluating physical health showed the greatest group differences in pain intensity (38.42%; p<0.0001) and the least in the general health status (24.48%; p<0.001). Those assessing mental health displayed statistically significant group differences in vital activity (24.78%; p<0.01).Conclusion. The patients receiving monotherapy with NSAIDs were found to have lower scores in all SF-36 scales than those on combination therapy with INF and NSAIDs.https://mrj.ima-press.net/mrj/article/view/495анкилозирующий спондилитингибиторы фактора некроза опухоли αкачество жизниопросник sf-36 |
| spellingShingle | Tatyana Alekseevna Raskina O A Pirogova Zh A Pivovarova Effect of infliximab on quality of life in patients with ankylosing spondylitis according to sf-36 questionnaire data Современная ревматология анкилозирующий спондилит ингибиторы фактора некроза опухоли α качество жизни опросник sf-36 |
| title | Effect of infliximab on quality of life in patients with ankylosing spondylitis according to sf-36 questionnaire data |
| title_full | Effect of infliximab on quality of life in patients with ankylosing spondylitis according to sf-36 questionnaire data |
| title_fullStr | Effect of infliximab on quality of life in patients with ankylosing spondylitis according to sf-36 questionnaire data |
| title_full_unstemmed | Effect of infliximab on quality of life in patients with ankylosing spondylitis according to sf-36 questionnaire data |
| title_short | Effect of infliximab on quality of life in patients with ankylosing spondylitis according to sf-36 questionnaire data |
| title_sort | effect of infliximab on quality of life in patients with ankylosing spondylitis according to sf 36 questionnaire data |
| topic | анкилозирующий спондилит ингибиторы фактора некроза опухоли α качество жизни опросник sf-36 |
| url | https://mrj.ima-press.net/mrj/article/view/495 |
| work_keys_str_mv | AT tatyanaalekseevnaraskina effectofinfliximabonqualityoflifeinpatientswithankylosingspondylitisaccordingtosf36questionnairedata AT oapirogova effectofinfliximabonqualityoflifeinpatientswithankylosingspondylitisaccordingtosf36questionnairedata AT zhapivovarova effectofinfliximabonqualityoflifeinpatientswithankylosingspondylitisaccordingtosf36questionnairedata |